Assuming that the occlusion of capillary vessels in autoimmune disorders is relevant well beyond mere thrombosis, we argue in favor of a more selective therapeutic approach in anticytokine therapy based on TNFR2-specific antagonists. Here, TNFRSF1B is linked to autoimmune disease.